CompletedPhase 3ACTRN12606000533594

Adjuvant tamoxifen - longer against shorter

Adjuvant tamoxifen longer against shorter (ATLAS) clinical trial in early breast cancer. Reliable assessment of the efficacy and safety of prolonging the use of adjuvant tamoxifen: a large, simple, randomised study.

Sponsor

Breast Cancer Trials

Enrollment

20,000 participants

Start Date

Jul 1, 1996

Study Type

Interventional

Conditions

Early Breast Cancer

Summary

Trials of adjuvant tamoxifen in women with early breast cancer have demonstrated a highly significant improvement in 10-year survival. However it is not yet known how long women with early breast cancer should continue to take adjuvant tamoxifen. The ATLAS trial will determine if it is better to stop taking tamoxifen after 5 years, or continue taking it for another 5 years (10 years in total).

Eligibility

Sex: FemalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study compares continuing tamoxifen treatment for a longer period versus stopping it sooner in women who have had surgery for early breast cancer. It is for women currently taking tamoxifen who appear cancer-free, where both the patient and doctor are uncertain about the best duration. There are no strict exclusion criteria beyond that.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Patients enter the trial after completing approximately 5 years of tamoxifen for early breast cancer and are randomised to either continue tamoxifen for a further 5 years or stop tamoxifen. The dosage of tamoxifen is recommended at 20mg.day orally unless the patient's clinician prefers a different dosage. Patients will continue to be followed for at least 5 years after completing treatment.